New Actavis/Bioton alliance to shake up diabetes market / Global managed-care offering to help bring down treatment costs for 366 million diabetics
Warsaw, Poland (ots) - Actavis and Bioton (WSE:BIO) announced today that they have formed a joint venture company for the development and registration of insulins, including analogue insulins. Within the framework of the joint-venture, Bioton will be responsible for the development and manufacture of insulin ...